J
Joachim Stangier
Researcher at Boehringer Ingelheim
Publications - 62
Citations - 11441
Joachim Stangier is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Dabigatran & Idarucizumab. The author has an hindex of 35, co-authored 62 publications receiving 10917 citations. Previous affiliations of Joachim Stangier include University of Navarra.
Papers
More filters
Journal ArticleDOI
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn,Joachim Stangier,Sebastian Haertter,Karl-Heinz Liesenfeld,Wolfgang Wienen,Martin Feuring,Andreas Clemens +6 more
TL;DR: Although there is no specific antidote to antagonise the anticoagulant effect of dabigatran, due to its short duration of effect drug discontinuation is usually sufficient to reverse any excessive anticogulant activity.
Journal ArticleDOI
Idarucizumab for Dabigatran Reversal
Charles V. Pollack,Paul A. Reilly,John W. Eikelboom,Stephan Glund,Peter Verhamme,Richard A. Bernstein,Robert Dubiel,Menno V. Huisman,Elaine M. Hylek,Pieter W. Kamphuisen,Jörg Kreuzer,Jerrold H. Levy,Frank W. Sellke,Joachim Stangier,Thorsten Steiner,Bushi Wang,Chak Wah Kam,Jeffrey I. Weitz +17 more
TL;DR: Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes and normalized the test results in 88 to 98% of the patients, an effect that was evident within minutes.
Journal ArticleDOI
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
TL;DR: The data suggest that dabigatran etexilate is a promising novel oral DTI with predictable PK and PD characteristics and good tolerability, and further investigation of dabig atran e Texilate for the treatment and prophylaxis of patients with arterial and venous thromboembolic disorders, acute coronary syndromes and other medical conditions is warranted.
Journal ArticleDOI
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Charles V. Pollack,Paul A. Reilly,Joanne van Ryn,John W. Eikelboom,Stephan Glund,Richard A. Bernstein,Robert Dubiel,Menno V. Huisman,Elaine M. Hylek,Elaine M. Hylek,Chak-Wah Kam,Chak-Wah Kam,Pieter Willem Kamphuisen,Jörg Kreuzer,Jerrold H. Levy,Gordon A. Royle,Frank W. Sellke,Joachim Stangier,Thorsten Steiner,Thorsten Steiner,Peter Verhamme,Bushi Wang,Laura Young,Jeffrey I. Weitz +23 more
TL;DR: In emergency situations, idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran.
Journal ArticleDOI
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
TL;DR: Exposure to dabigatran is increased by renal impairment and correlates with the severity of renal dysfunction, and a decrease in the dose and/or an increase in the administration interval in these patients may be appropriate.